Biotech CEOs: Can Scientist-Founders Remain In Charge?
A New Breed Of Scientist-Founder: PhD-Carrying Entrepreneurs Who Want To Translate Their Ideas Into Companies
Executive Summary
Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.
You may also be interested in...
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Re-Thinking Rare Disease
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.